Librela for Dogs Cost: 2026 Clinic Prices by Weight, $74–$174

How much does Librela cost? Published clinic prices (2026)

Most cost guides give a range without saying where it comes from. We looked for practices that post their own Librela price and found three US clinic price lists plus one hospital blog that states a range. Every figure was read on the practice's own page on October 30, 2026; only one page carries an effective date.

Range from the three price lists: $74 (a dog under 11 lb in Los Angeles) to $174 (the top of the two-vial tier in Xenia). The San Ramon blog runs higher, to "$250 or more", but it is a general statement, not a fee schedule. The sources differ, and four practices are not a national sample, so we do not average them.

Why Librela cost depends on your dog's weight: the label's vial chart

Librela (bedinvetmab) is a canine monoclonal antibody that binds nerve growth factor (NGF), a protein the FDA describes as elevated in dogs with osteoarthritis. It is given as an injection under the skin once a month and is dosed to reach a minimum of 0.23 mg per lb (0.5 mg/kg). Five strengths exist (5, 10, 15, 20 and 30 mg/mL), each a 1 mL single-use vial. The label's dosing table (DailyMed, updated February 21, 2025) decides the vials:

Clinic tiers use rounded pounds, so ask which tier applies if your dog sits on a border. Three label rules explain most price differences:

• Each band is built around the minimum dose. The band's top weight gets exactly 0.5 mg/kg (5 mg for a 10 kg dog, our arithmetic), and lighter dogs in the band get more. A vet does not draw a "smaller" dose for a lighter dog inside a band; the full vial goes in.
• Vials are single use. The product has no preservative, so once a vial is punctured it is used immediately and the rest is thrown away. That is why a 7 lb dog still pays for a whole 5 mg vial.
• The two-vial jump. Above 132.3 lb the label calls for two vials drawn into one syringe, which is where Docton's price jumps from $110–$115 to $166–$174.

The label lists cartons of 2 or 6 vials and refrigerated storage at 36–46°F. Zoetis says doses are distributed to veterinary offices, and the FDA's approval announcement says Librela is "only available by prescription from a licensed veterinarian".

Librela cost per month and per year: worked examples

Librela is a once-a-month injection, so the monthly cost is the injection price plus whatever visit fee your clinic charges. Below are Patify calculations from the published prices, for 12 injections a year. They are not quotes.

The FDA field studies dosed every 28 days; a strict four-week cycle means 13 visits a year, so add one injection. The label also says effects beyond 9 months have not been evaluated, so plan regular reviews with your vet.

A first year with visit fees: 60 lb dog

None of the price pages says whether a fee is added at every monthly injection. Here is how totals move under three set-ups, using each clinic's own published fees (Patify calculation):

The same 60 lb dog can cost about $1,400 or over $2,100 in year one at the same two clinics, depending only on how visits are billed.

Exam, recheck and technician fees at the same clinics

Only fees printed on the same pages as the Librela prices are listed. If your vet recommends bloodwork or X-rays first, ask for those prices separately; none of these pages ties them to Librela.

The label tells vets to review the Client Information Sheet with the owner "prior to each injection". That is a conversation, not necessarily a full exam, so ask how your clinic books it.

The first two injections: what a fair trial costs

Do not judge Librela on the first shot. The FDA's Freedom of Information summary concludes that the field-study evidence shows Librela is effective "when at least two doses are given 28 days apart". Zoetis says some dogs improved "as soon as 7 days after the first injection" while others may not respond until after the second.

Before the second dose, note what changed at home: rising from bed, stairs, walk length, jumping into the car. Owners in the FDA studies scored this kind of daily activity, and your notes help decide whether month three is worth paying for.

What the FDA studies showed you are paying for

Librela was approved on May 5, 2023 (NADA 141-562) for "the control of pain associated with osteoarthritis in dogs". It does not cure arthritis. Approval rested on two field studies, one in the US and one in the EU, in which half the dogs got Librela and half got saline every 28 days for three doses. Owners scored pain with the Canine Brief Pain Inventory; a dog counted as a treatment success if its pain severity score fell by at least 1 and its pain interference score by at least 2.

In the US study the Day 28 difference was not statistically significant (P = 0.0719); in the EU study it was (45.2% vs 17.0%). The FDA approved Librela on the weight of both studies, noting that success rose after the second dose and held through Day 84. Roughly half or a bit more of treated dogs met the bar, and a sizable share of saline dogs did too, which is why a two-dose trial matters before a year of payments.

The Merck Veterinary Manual (last updated August 2025) says bedinvetmab "is useful for dogs with moderate to severe clinical signs" and that its use in mild cases "remains controversial". If your dog's arthritis is mild, ask whether cheaper first steps make sense before a monthly injection.

Safety: the FDA Dear Veterinarian letter and the 2025 label update

A bad reaction adds vet bills and can end treatment, so the safety picture belongs in any cost decision. The timeline from FDA documents:

The Dear Veterinarian letter lists reported "ataxia, seizures, other neurologic signs, including but not limited to, paresis, recumbency, urinary incontinence", plus increased urination and thirst (polyuria, polydipsia), and says death, including euthanasia, was reported in some cases. Reports describe events; they do not prove the drug caused each one. The letter also notes that FDA's veterinary center "does not currently have the authority to mandate safety-related labeling changes".

The current label's Post-Approval Experience (2025) section lists, in decreasing order of reporting frequency: neurological (ataxia, seizures, paresis, proprioception deficits, paralysis), general (anorexia, lethargy, recumbency), urinary (polydipsia, polyuria or frequent urination, urinary incontinence), gastrointestinal (vomiting, diarrhea) and musculoskeletal signs (muscle weakness, muscle tremors, lameness). In some cases death, including euthanasia, was reported; frequency cannot be reliably estimated from these reports.

Zoetis states that "Globally, adverse events have been reported post-approval at a rate of between 1 to 10 times per 10,000 doses distributed", noting that reporting is voluntary. That is the maker's figure, not an FDA estimate.

Other label points that decide whether Librela fits your dog:

• Do not use in breeding, pregnant or lactating dogs (contraindication).
• Not evaluated in dogs under 12 months, or in dogs with a cruciate ligament rupture in the six months before starting.
• Safety alongside NSAIDs has not been established in dogs; in people, rapidly progressing osteoarthritis was reported with anti-NGF antibodies, more often with long-term NSAID use.
• The label recommends an exercise plan, because dogs that were inactive before treatment may be at higher injury risk once they feel better.

Report adverse events to Zoetis at 1-888-963-8471 or to FDA at fda.gov/reportanimalae, as the FDA letter explains. For both drugs side by side, see our earlier Solensia and Librela overview.

Ways to lower the cost of Librela that actually exist

1. Join Zoetis Petcare Rewards (free). Zoetis's Librela offer page lists 100 points per injection at the Bronze tier and 150 at Gold, with "$1 for every 10 points to spend at the vet". That is $10 to $15 back per injection, or about $120 to $180 over 12 injections. The page does not explain how tiers are reached, so count on the Bronze figure.
2. Ask for a technician visit for repeat injections. Southpaw lists a $20 technician visit versus a $63 recheck; Docton charges $15–$25 with a technician versus a $53 progress exam. Your vet decides whether that is appropriate for your dog.
3. Compare the weight-band price, not the headline. For an 80 to 132 lb dog, Docton's $110–$115 tier was cheaper than Southpaw's $125–$137 tiers. For a 20 lb dog it was the other way round.
4. Use the two-dose trial. If you and your vet see no meaningful change after two doses, discuss stopping.
5. Keep your dog lean. Merck calls weight optimization "the primary preventive method" against osteoarthritis in dogs. The dose band is set by your vet from the scale at each visit; never adjust anything yourself.
6. Be careful with financing. Monthly treatment on a promotional credit plan can backfire; read our guide to deferred-interest vet financing first.

Does pet insurance cover Librela?

Insurers rarely name Librela, so check two things in the policy: whether prescription drugs for covered conditions are included, and whether your dog's arthritis counts as pre-existing. What insurers state on their own pages (accessed October 30, 2026):

If your dog already has an arthritis note in its records, a new policy will probably not pay for Librela. Our guides to waiting periods and pre-existing condition denials and to whether pet insurance is worth it go deeper.

Alternatives your vet may discuss (and how they compare on cost)

We do not give doses for any of these; they are prescription decisions for your vet. What the Merck Veterinary Manual says about osteoarthritis treatment in dogs:

Merck cites a meta-analysis finding "no evidence of a beneficial effect" for glucosamine and chondroitin, while PSGAG or pentosan polysulfate may help dogs in earlier stages. Combining Librela with an NSAID is your vet's call: the label says the combination's safety "has not been established in dogs".

Not every limp is arthritis; our guide to a dog limping but not in pain explains other causes. A ramp for the car or bed is a simple home help: see our DIY dog ramp guide. On the itch antibody Cytopoint, see our Apoquel vs Cytopoint comparison; Librela's safety with other monoclonal antibodies has not been evaluated.

Questions to ask before the first Librela injection

• What is the vial price for my dog's exact weight, and which tier is my dog in if the weight is on a border?
• Is each monthly visit billed as an exam, a recheck, a technician visit, or the injection only?
• After two doses, how will we decide whether to continue?
• Do you take Zoetis Petcare Rewards cards for payment?

Have a stiff older cat too? See our Solensia for cats cost guide.

Frequently asked questions

Sources (accessed October 30, 2026)

• DailyMed (US National Library of Medicine): LIBRELA (bedinvetmab injection) label, Zoetis Inc., NADA 141-562, updated February 21, 2025.
• US FDA: Freedom of Information Summary, NADA 141-562, approved May 5, 2023.
• US FDA CVM update: "FDA Approves First Monoclonal Antibody for Dogs with Osteoarthritis Pain", May 5, 2023.
• US FDA: Dear Veterinarian Letter on adverse events reported in dogs treated with Librela, current as of December 16, 2024.
• US FDA CVM: Pharmacovigilance Review of Librela (DPS-2024-141), September 10, 2024.
• US FDA: Animal Drug Safety-Related Labeling Changes (Librela entry February 18, 2025), current as of October 13, 2026.
• Zoetis Petcare: Librela product page, Librela rewards offer, Petcare Rewards page.
• Merck Veterinary Manual: Osteoarthritis in Dogs and Cats, last updated August 2025.
• Price pages: Southpaw Vets (Los Angeles, CA); Docton Animal Clinic (Xenia, OH); Animal Hospital Southwest (Fort Worth, TX), effective February 17, 2026; Bishop Ranch Veterinary Center & Urgent Care (San Ramon, CA) Librela blog post.
• Embrace: Prescription Drug Coverage. Lemonade: pre-existing conditions and waiting periods pages, updated October 13, 2026.
• All monthly, yearly and trial totals are Patify calculations from the published prices, not quotes.